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Abstract
Background: Evidence concerning third-line life-prolonging drugs (LPDs) in the treat-
ment of metastatic castration-resistant prostate cancer (mCRPC) patients is incomplete.
Objective: To evaluate third-line LPD outcomes in a real-world cohort of mCRPC
patients, identify variables associated with overall survival (OS), and establish a prog-
nostic model.
Design, setting, and participants: Patients with mCRPC who were progressive on
second-line LPD before July 1, 2017 were retrospectively identified from the Dutch
Castration-resistant Prostate Cancer Registry (CAPRI) and followed until December
31, 2017.
Outcome measurements and statistical analysis: Association of potential risk factors
with OS was tested by Cox proportional hazard models after multiple imputation of
missing baseline characteristics. A predictive score was computed from the regression
coefficient and used to classify patients into risk groups.ns:
-linResults and limitatio
(60%) received thirdy These authors shared the first authorship.
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2405-4569/© 2020 European Association of Urology. Published by Elsevier  Of 1011 mCRPC patients progressive on second-line LPD, 602
e LPD. Patients receiving third-line LPD had a more favorablee Life-prolonging Drug Treatment in a Real-world Metastatic
 Dutch Castration-resistant Prostate Cancer Registry. Eur Urol
B.V. All rights reserved.
prognostic profile at baseline and longer median OS than patients with best supportive
care (10.4 vs 2.4 mo, p < 0.001). Eastern Cooperative Oncology Group performance
status 1 and 2 (hazard ratio [HR] 1.51, p < 0.007 and HR 3.08, p < 0.001, respectively),
opioid use (HR 1.55, p = 0.019), visceral metastases (HR 2.09, p < 0.001), hemoglobin
<7 mmol/l (HR 1.44, p < 0.002), prostate-specific antigen 130 mg/l (HR 1.48,
p = 0.001), alkaline phosphatase 170 U/l (HR 1.52, p < 0.001), and lactate dehydroge-
nase 250 U/l (HR 1.44; p = 0.015) were associated with shorter survival. Harrell’s
C-index was 0.74. The median OS values for low-, low-intermediate-, high-intermedi-
ate-, and high-risk groups were 14, 7.7, 4.7, and 1.8 mo, respectively. Limitations include
the retrospective design.
Conclusions: We developed a prognostic model and identified a subgroup of patients in
whom third-line LPD treatment has no meaningful benefit. Our results need to be
confirmed by prospective clinical trials.
Patient summary: We reported outcomes from third-line life-prolonging drugs in
metastatic prostate cancer patients and developed a prognostic model that could be
used to guide treatment decisions.
© 2020 European Association of Urology. Published by Elsevier B.V. All rights
reserved.
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Prostate cancer is the most common cancer among men in
the Western world [1]. Part of these patients will eventually
progress and develop metastatic castration-resistant pros-
tate cancer (mCRPC) [2]. In 2004, docetaxel, a member of
the taxane drug class, was the first treatment to improve
overall survival (OS) of mCRPC patients [3]. In the past years,
several new therapeutic agents, including cabazitaxel, abir-
aterone acetate, enzalutamide, and radium-233, have also
been registered for the treatment of mCRPC based on a
survival benefit. The outcomes of these life-prolonging
drugs (LPDs) as first- and/or second-line (post-docetaxel)
treatment have been well established [4–9].
It is commonpractice to use these drugs as a third-line LPD
treatment, after first- and second-line LPD treatment, in the
hope to obtain a cumulative benefit [10]. To date, randomized
controlled trials of third-line LPDs in mCRPC patients are
scarce [11]. The reports on third-line LPDs are particularly
retrospective andbased on smallcohorts of patients receiving
one specific third-line LPD [12–16]. Patients with mCRPC who
are on third-line LPD may have worse outcomes, compared
with those on first- and second-line LPD treatment, due to
more advanced stages in general, decreased performance
status, worse tolerance to treatments [17], and possible
cross-resistance [18].
Thus, third-line LPDs might not be appropriate for all
patients. Selection of patients with mCRPC who will benefit
from third-line LPD treatment is crucial to improve out-
comes, reduce unnecessary toxicity, improve quality of life
(QoL), and reduce costs [19]. Prediction of treatment out-
come may allow for better patient selection. Nevertheless,
current prognostic models for survival using clinical and
laboratory baseline variables in mCRPC patients have been
described only in first- or second-line LPDs [20–23].
The aim of this retrospective study was to evaluate
outcomes of third-line LPD treatment in a real-world cohort
of mCRPC patients, to identify clinical and laboratory vari-
ables associated with survival, and to finally assess the
impact of these variables in a risk score.Please cite this article in press as: Notohardjo JCL, et al. Third-lin
Castration-resistant Prostate Cancer Population: Results from the
Focus (2020), https://doi.org/10.1016/j.euf.2020.03.0092. Patients and methods
2.1. Study design and setting
Castration-resistant Prostate Cancer Registry (CAPRI) is an
investigator-initiated, observational, multicenter cohort
study in 20 hospitals in The Netherlands. The study design
has been previously described [24]. Patients with mCRPC
were included retrospectively from January 1, 2010 until
December 31, 2015. Metastatic CRPC was defined either by
the criteria set by the European Association of Urology [25]
or by the treating physician. The study is registered in the
Dutch Trial Registry as NL3440 (NTR3591).
2.2. Objectives
The aim of this study is to investigate the outcomes of third-
line LPD treatment in a real-word population of mCRPC
patients, identify clinical and laboratory variables related to
survival outcomes, and assess the impact of these variables
in a risk score.
2.3. Participants
Metastatic CRPC patients with progressive disease on or
after a second-line LPD, before July 1, 2017, were included in
the analysis. All patients had received two lines of LPD
treatment, of which at least one of the two previous lines
was docetaxel. They were categorized into two groups:
patients receiving a third-line LPD and patients receiving
best supportive care (BSC).
Patients previously treated with docetaxel for hormone-
sensitive metastatic prostate cancer (n = 14) were excluded
from the analysis.
2.4. Follow-up and data collection
Predefined and readily available data from medical records
were retrospectively collected by trained data managers.
Baseline characteristics were included in the analysis if theye Life-prolonging Drug Treatment in a Real-world Metastatic
 Dutch Castration-resistant Prostate Cancer Registry. Eur Urol
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date after a second-line LPD. All patients were followed
until death, loss to follow-up, or December 31, 2017. Follow-
up duration was calculated as the time from the date of
progression on a second-line LPD to the last recorded date.
2.5. Outcomes
Outcomes were OS, treatment duration (TD), and prostate-
specific antigen (PSA) response. OS was calculated in
months from the date of progression after second-line
LPD treatment to the date of death from any cause. Patients
alive at the end of the study or lost to follow-up were
censored at the last recorded date.
TD was defined as the interval between the start and stop
of third-line LPD treatment. If the stop date was unknown,
TD was specified as the time from the start of third-line LPD
to the start of next treatment, or as the time from the start of
third-line LPD to the end of follow-up if third-line treatment
was the last treatment. Patients on treatment at the end of
follow-up were censored at the last recorded date.
PSA response was defined as the maximum change from
baseline PSA levels (in percentages) without confirmation
of a second measure. In case no decline was present,
responses were measured at 12 wk (according to Prostate
Cancer Clinical Trials Working Group 3 criteria for response
measurement [26]) or if treatment was <12 wk, at the end
of treatment or start of next treatment. PSA response was
defined as a 50% PSA decline from baseline.
2.6. Statistical analysis
Descriptive statistics were performed. The t test (or Mann–
Whitney U test for nonparametric variables) was used for
continuous variables and the Pearson chi-square was used
for categorical variables. OS and TD were estimated using
the Kaplan–Meier method and were compared between
groups using the log-rank test. A waterfall plot was made
to indicate PSA response. Missing baseline characteristics
were imputed using multiple imputation with Monte Carlo
Markov Chain method. Selection of prognostic factors was
based on clinical applicability (routinely collected and used
by clinicians), previous research, and expert opinion
[27]. Continuous variables were categorized using the
median cutoff or clinically applicable cutoffs. Multivariable
Cox proportional hazard analysis using a backward stepwise
procedure was performed on pooled data for OS. A simpli-
fied prediction rule was obtained by rounding the regres-
sion coefficients to half points, which were multiplied by
two for easier clinical applicability. A risk score for the
prediction of OS was then calculated for each patient.
Patients could be categorized into different risk groups
based on the survival curves of each risk score. The prog-
nostic performance of the prediction model was evaluated
using Harrell’s concordance index (C-index) in the original
dataset. A p value of 0.05 was considered statistically
significant. Statistical analyses were performed using IBM
SPSS Statistics, version 22.0 (SPSS Inc., Chicago, IL, USA).Please cite this article in press as: Notohardjo JCL, et al. Third-lin
Castration-resistant Prostate Cancer Population: Results from the
Focus (2020), https://doi.org/10.1016/j.euf.2020.03.0093. Results
At the end of the study, 3616 CRPC patients were included in
20 hospitals. A total of 1011 mCRPC patients (28%) had
progression on or after a second LPD treatment and were
included in the analysis. At database cutoff, 826 deaths
(82%) had occurred, 127 patients (13%) were lost to
follow-up, and 58 patients (6%) were still alive.
All patients were previously treated with docetaxel and
with abiraterone acetate (n = 525, 52%), enzalutamide
(n = 282, 28%), cabazitaxel (n = 155, 15%), docetaxel rechal-
lenge (n = 31, 3.0%) or radium-223 (n = 18, 2.0%).
Of these 1011 mCRPC patients, 602 (60%) received a third-
line LPD. The third-line LPD consisted of cabazitaxel (n = 213,
35%), abiraterone acetate (n = 137, 23%), enzalutamide
(n = 129, 21%), radium-223 (n = 78, 13%), and docetaxel
(n = 45, 8.0%). An overview of previous treatment lines and
third-line treatment is provided in Supplementary Table 1.
3.1. Baseline characteristics
Baseline characteristics of mCRPC patients at the progres-
sion date of a second-line LPD, according to the subsequent
third-line LPD or not, are shown in Table 1. Patients receiv-
ing a third-line LPD had a more favorable prognostic profile
(significantly younger, better Eastern Cooperative Oncology
Group performance status [ECOG PS], less opioid use, less
visceral metastases, higher hemoglobin [Hb], lower alkaline
phosphatase [ALP], and lower lactate dehydrogenase [LDH])
compared with patients who received BSC.
3.2. OS and risk-scoring system
The median OS (mOS) from progression on a second-line
LPD was 6.5 mo (95% confidence interval [CI] 5.9–7.2). The
mOS was longer for patients receiving a third-line LPD
(10.4 mo, 95% CI 9.2–11.6) compared with patients who
received BSC (2.4 mo, 95% CI 2.1–2.7; Fig. 1).
Univariable analysis revealed baseline ECOG PS, opioid
use, symptoms, visceral metastases, lymph node metasta-
ses, Hb, PSA, ALP, LDH, and period from castration to CRPC as
being significant variables for the prediction of survival in
mCRPC patients progressing on a second-line LPD (Table 2).
The multivariable Cox regression analysis of pooled data
identified seven variables independently associated with OS:
ECOG PS of 1 and 2 (HR 1.51, 95% CI 1.13–2.00, p = 0.007 and
HR 3.08, 95% CI 2.31–4.10, p < 0.001, respectively), opioid use
(HR 1.55, 95% CI 1.10–2.19, p = 0.019), visceral metastases
(HR 2.09, 95% CI 1.76–2.49, p < 0.001), Hb <7.0 mmol/l
(HR 1.44, 95% CI 1.15–1.84, p = 0.002), PSA 130 mg/l
(HR 1.48, 95% CI 1.20–1.82, p = 0.001), ALP 170 U/l (HR 1.52,
95% CI 1.26–1.84, p < 0.001), and LDH >250 U/l (HR 1.44, 95%
CI 1.09–1.90, p = 0.015); these were related to worse survival and
included in the final model. The Harrell’s C-index was 0.74.
Based on their regression coefficients, we assigned
a score of 1 point to ECOG PS of 1, opioid use, Hb
< 7.0 mmol/l, PSA  130 mg/l, ALP  170 U/l, and LDH
> 250 U/l. A score of 2 points was assigned to ECOG PS  2 ande Life-prolonging Drug Treatment in a Real-world Metastatic
 Dutch Castration-resistant Prostate Cancer Registry. Eur Urol
Table 1 – Baseline characteristics at the time of progression after a second-line LPD in mCRPC patients according to receiving a third-line LPD
or best supportive care.
Characteristics Total group of patients
progressive after a
second-line LPD
Missing Best supportive
care
Missing Third-line LPD Missing p value
(n = 1011) (n = 409) (n = 602)
Age (yr) 71.6  7.5 21 (2.1) 73.0  7.8 0 71.0  7.3 21 (3.5) 0.032
ECOG PS 508 (50) 229 (56) 279 (46) <0.001
0 93 (9) 15 (4) 78 (13)
1 280 (28) 67 (16) 213 (35)
2 130 (13) 98 (24) 32 (5)
Opioid use 219 (22) 605 (60) 127 (31) 225 (55) 92 (12) 380 (63) <0.001
Symptomatic 704 (70) 81 (8) 346 (85) 13 (3) 358 (60) 68 (11) <0.001
Metastatic site
Bone 871 (86) 96 (10) 355 (87) 41 (10) 516 (86) 55 (9) 0.139
Visceral 169 (17) 493 (49) 91 (22) 202 (49) 78 (13) 291 (48) <0.001
Lymph nodes 469 (46) 382 (38) 195 (48) 163 (40) 274 (46) 219 (36) 0.030
Hemoglobin (mmol/l) 7.1  1.2 303 (30) 6.8  1.2 111 (27) 7.4  1.1 192 (32) <0.001
Platelets (109/l) 250 (193–315) 314 (31) 238 (167–322) 117 (29) 256 (205–313) 197 (33) 0.032
Prostate-specific antigen
(mg/l)
133 (42–413) 126 (13) 174 (42–491) 64 (16) 118 (42–358) 62 (10) 0.058
Alkaline phosphatase (U/l) 170 (99–353) 182 (18) 260 (128–506) 72 (18) 139 (88–253) 110 (18) <0.001
Lactate dehydrogenase (U/l) 289 (213–420) 411 (41) 389 (241–730) 154 (38) 251 (203–360) 257 (43) <0.001
ECOG PS = Eastern Cooperative Oncology Group performance status; LPD = life-prolonging drug; mCRPC = metastatic castration-resistant prostate cancer;
SD = standard deviation.
Data are presented as mean  SD, median (interquartile range), or n (%).
Fig. 1 – Kaplan-Meier curves and at-risk tables for overall survival (OS) from progression after a second-line LPD (A) for the total group (n = 1011), (B)
classified by third-line LPD (n = 602) or best supportive care (n = 409). The p values were obtained from log-rank tests for the homogeneity of Kaplan-
Meier curves between third-line LPD and best supportive care.
CI = confidence interval; LPD = life-prolonging drug; OS = overall survival.
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Taking into account the survival curves of the calculated
risk scores, patients could be categorized into different risk
groups: low-risk (score 0), low-intermediate risk (score 1–3),
high-intermediate risk (score 4–6), and high-risk (score 7–9;
Supplementary Table 2B). The low-risk group includedPlease cite this article in press as: Notohardjo JCL, et al. Third-lin
Castration-resistant Prostate Cancer Population: Results from the
Focus (2020), https://doi.org/10.1016/j.euf.2020.03.009103 patients (10%), the low-intermediate-risk group included
467 patients (46%), the high-intermediate-risk group
included 341 patients (34%), and the high-risk group included
56 patients (6%). Median survival times for these low-, low-
intermediate-, high-intermediate-, and high-risk groups
were 14.0 mo (95% CI 10.7–17.3), 7.7 mo (95% CI 6.6–8.9),e Life-prolonging Drug Treatment in a Real-world Metastatic
 Dutch Castration-resistant Prostate Cancer Registry. Eur Urol
Table 2 – Univariable and multivariable analyses of different prognostic variables for overall survival in patients with mCRPC progression
after a second-line LPD.
Variable n Event Censored Missing Univariable analysis a Multivariable analysis a,b
Hazard ratio
(95% CI)
p value Hazard ratio
(95% CI)
p value b c Points
ECOG PS 503 420 83 508 <0.001
0 93 1 1 0
1 280 1.74 (1.33–2.29) 1.51 (1.13–2.00) 0.007 0.409 1
2 130 4.55 (3.35–6.18) 3.08 (2.31–4.10) <0.001 1.123 2
Opioid use 406 350 56 605 <0.001 0.019
No 187 1 1 0
Yes 219 2.18 (1.75–2.73) 1.55 (1.10–2.19) 0.438 1
Symptomatic 925 754 171 86 <0.001
No 224
Yes 701 2.07 (1.73–2.47)
Visceral metastases 511 409 102 500 <0.001 <0.001
No 344 1 1 0
Yes 167 2.13 (1.73–2.62) 2.09 (1.76–2.49) 0.738 2
Lymph node metastases 622 508 114 389 0.002
No 158 1
Yes 464 1.38 (1.12–1.69)
Hemoglobin (mmol/l) 708 594 114 303 <0.001 0.002
<7 307 2.22 (1.88–2.62) 1.44 (1.15–1.84) 0.372 1
7 401 1 1 0
Platelets (109/l) 697 584 113 314 0.535
<250 344 1
250 353 1.05 (0.89–1.24)
Prostate-specific antigen (mg/l) 885 723 162 126 <0.001 0.001
<130 441 1 1 0
130 444 1.73 (1.49–2.00) 1.48 (1.20–1.82) 0.393 1
Alkaline phosphatase (U/l) 833 682 151 178 <0.001 <0.001
<170 415 1 1 0
170 418 2.23 (1.91–2.60) 1.52 (1.26–1.84) 0.421 1
Lactate dehydrogenase (U/l) 600 505 95 411 <0.001 0.015
<ULN 236 1 1 0
ULN 364 2.24 (1.86–2.69) 1.44 (1.09–1.90) 0.365 1
Time from castration to CRPC
(mo)
988 806 182 23 0.012
<12 475 1.19 (1.04–1.37)
12 513 1
B = beta regression coefficient; CI = confidence interval; CRPC = castration-resistant prostate cancer; ECOG PS = Eastern Cooperative Oncology Group
performance status; LPD = life-prolonging drug; mCRPC = metastatic castration-resistant prostate cancer; n = number of patients; ULN = upper limit of normal.
a Cox regression model.
b The final sample used in the multivariate analysis consisted of 1011 patients; 826 patients died and 185 were censored.
c The coefficient of each variable was rounded to half point and then multiplied by a constant (2) for easier clinically applicability.
Fig. 2 – Kaplan-Meier curves and risk tables for overall survival (OS) from progression after a second-line LPD according to the four risk groups for (A)
the total group (n = 1011), (B) patients receiving a third-line LPD (n = 602), and (C) patients receiving best supportive care (n = 409).
CI = confidence interval; LPD = life-prolonging drug; OS = overall survival.
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tively (p < 0.001; Fig. 2A).
A third-line LPD was started in 69% patients (71 out of
103) in the low-risk group, 64% patients (299 out of 467) in
the low-intermediate-risk group, 53% patients (181 out of
341) in the high-intermediate-risk group, and 30% patients
(17 out of 56) in the high-risk group. The mOS for these risk
groups, according to whether or not treated with a third-
line LPD, are depicted in Fig. 2.
A nomogram, integrating the significant independent
variables for OS, is provided in Supplementary Figure 1.
3.3. TD and PSA response of third-line LPD treatment
At the end of follow-up, 26 patients (4.3%) with a third-line
LPD were still on treatment. The median TD (mTD) for a
third-line LPD was 3.3 mo (95% CI 3.0–3.5). PSA decline on
the third-line LPD was assessable in 560 (93%) patients and
observed in 130 (22%) patients.
The mTD for the four risk groups (low-, low-intermediate-,
high-intermediate-, and high-risk groups) were 4.6 mo (95%
CI 3.8–5.4), 3.4 mo (95% CI 3.2–3.6), 2.7 mo (95% CI 2.4–3.0),
and 1.4 mo (95% CI 1.1–1.7), respectively (p < 0.001; Fig. 3).
PSA response rates (>50% PSA response) were 24% (18/76
patients), 22% (66/301 patients), 23% (41/181 patients), and
6% (one/17 patients), respectively. Waterfall plot of the PSA
responses are shown in Fig. 4.
4. Discussion
To our knowledge, this is the first large multicenter real-
world cohort, evaluating the outcomes of mCRPC patientsFig. 3 – Kaplan-Meier curves and at-risk tables for the treatment duration of a
and (B) according to the four risk groups.
CI = confidence interval; LPD = life-prolonging drug; TD = treatment duration.
Please cite this article in press as: Notohardjo JCL, et al. Third-lin
Castration-resistant Prostate Cancer Population: Results from the
Focus (2020), https://doi.org/10.1016/j.euf.2020.03.009progressing on a second-line LPD, treated according to the
views and opinions of their treating physicians.
We observed the mOS of 6.5 mo from progression of
second-line LPD. The mOS was longer in patients with a
third-line LPD than in patients receiving BSC (10.4 vs
2.4 mo), but TD was short (3.3 mo) and PSA response
was low (22%). Our results confirm the potential cumulative
survival benefit (mOS 7.1–15.8) of previous retrospective
studies on third-line LPD treatment [13–15].
Pivotal phase 3 trials on first- and second-line LPD
treatment in mCRPC patients reported the mOS of 14.0–
34.7 mo. The difference in OS can partially be explained by
the fact that patients treated in trials notably differ from
patients who receive standard treatment options only [24]
and the more advanced disease state of patients after two
systemic treatment lines. This is reflected by poor perfor-
mance score, high disease burden, and high ALP, LDH, and
PSA. As mCRPC progresses, disease control becomes more
difficult [28]. Possible cross-resistance with previous treat-
ments can further decrease treatment effect [18]. Moreover,
tolerability to new systemic treatments can be worse [17],
leading to early discontinuation.
Evidence concerning optimal sequencing of third-line
LPDs is limited, but suggests that patients may not respond
to androgen receptor–targeted therapies (ARTs; abiraterone
or enzalutamide) in third line after progression on prior
ARTs due to cross-resistance [10,17,29]. This is recently
prospectively confirmed by a study of de Wit et al. [11],
which reported increased mOS in patients receiving caba-
zitaxel compared with those receiving an ART (13.6 vs
11.0 mo) after prior docetaxel and the other ART. Since all
patients had progression on an alternative ART within
12 mo, they were not comparable with our study third-line LPD (A) for all patients receiving a third-line LPD (n = 602)
e Life-prolonging Drug Treatment in a Real-world Metastatic
 Dutch Castration-resistant Prostate Cancer Registry. Eur Urol
Fig. 4 – Waterfall plots of maximum PSA changes from baseline for patients treated with a third-line LPD (n = 602).
LPD = life-prolonging drug; PSA = prostate-specific antigen.
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prognostic variables associated with survival, namely ECOG
PS, opioid use, visceral metastases, Hb, PSA, ALP, and LDH.
These variables were able to distinct four risk groups (low-,
low-intermediate-, high-intermediate-, and high-risk) for
patients who had progressive disease after a second-line
LPD, with corresponding median survival times of 14.0, 7.7,
4.7, and 1.8 mo, respectively (p < 0.001).
Especially, high-risk patients had remarkably short mOS.
Moreover, high-risk patients treated with a third-line LPD
had worse mOS than patients receiving BSC in low- or
low-intermediate-risk groups. These results suggest that
high-risk patients may derive no meaningful benefit from
third-line LPDs in clinical practice, which is supported by
the short mTD and low PSA responses. Therefore, high-risk
patients should not be treated with third-line LPDs; instead,
they should be treated with BSC.
Our prognostic model allows for the stratification of four
risk groups with widely differing mOS. It is important for
physicians to consider these different survival times in
medical decision making. Proper patient selection for
third-line LPD treatment is crucial to improve outcomes,
reduce unnecessary toxicity, and improve QoL. Also, carefulPlease cite this article in press as: Notohardjo JCL, et al. Third-lin
Castration-resistant Prostate Cancer Population: Results from the
Focus (2020), https://doi.org/10.1016/j.euf.2020.03.009consideration is warranted considering possible low cost
effectiveness.
This study is not without limitations. First, our results are
limited by the absence of previously identified risk factors
such as albumin level [27]. However, albumin is not a
routinely assessed parameter in real-world clinical practice.
Moreover, many patients had missing values of one or more
baseline variables at progression on second-line LPD due to
the retrospective nature of the study. Imputation of missing
baseline data offers a valid solution for multivariable anal-
ysis [30]. Second, the effect of third-line LPD in other out-
comes such as QoL and cost effectiveness could not be
included in this analysis. Lastly, the identified prognostic
model has not yet been externally validated and is therefore
not yet suitable for clinical use.
Nevertheless, our prognostic model was developed using
a large number of patients with mCRPC who were progres-
sive after second-line LPD, and the number of deaths in the
pooled analysis was substantial, providing good statistical
power. Furthermore, this prognostic model is based on
readily available clinical and laboratory variables, and risk
groups can be calculated easily. Although our prognostic
model is based on retrospective data, it was able to identifye Life-prolonging Drug Treatment in a Real-world Metastatic
 Dutch Castration-resistant Prostate Cancer Registry. Eur Urol
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EUF-897; No. of Pages 9four risk groups with differing survival times, suggesting
that the identified variables may assist in the selection of
patients for third-line LPD treatment in daily clinical prac-
tice and thereby improving efficacy of these potentially
toxic and expensive LPD.
5. Conclusions
Third-line LPDs might not be appropriate for all mCRPC
patients, which is supported by the short mTD and low PSA
responses observed in our study. We developed a simple
prognostic model, based on routinely used clinical and
laboratory parameters, and identified a high-risk subgroup
in whom no meaningful benefit from third-line LPD is
derived in clinical practice. Our results need to be confirmed
by further prospective trials.
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